# nature portfolio

Corresponding author(s):	Snehajyoti Chatterjee and Ted Abel
Last updated by author(s):	Sep 1, 2023

# **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

<u> </u>			
St	:at	181	יור כ

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	$\square$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
$\boxtimes$	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
$\boxtimes$	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i> ), indicating how they were calculated
	Our was collection on statistics for histories contains articles on many of the points above

### Software and code

Policy information about availability of computer code

Data collection

Leica CM3050 S cryostat, Olympus BX61 Upright Microscope, Illumina NovaSeq 6000 SP, Odyssey Infrared Imaging System (LI-COR), Olympus FV3000 confocal microscope, QuantStudio 7 Flex Real-Time PCR system.

Data analysis

Visium imaging: Olympus CellSens software v.3.2.

Bulk RNA-seq processing: BCBio RNA-sequencing pipeline v1.2.4, STAR aligner v2.6.1, FastQC v.0.11.8, edgeR's quasi-likelihood pipeline, EDASeq v2.30.0, RUVSeq v.1.30.0.

Visium data processing: Space Ranger v.1.3.1, STAR v.2.7.10a, Partek Flow package (Build version 10.0.21.0621), Cytoscape 3.9.0 software.

SPLIT-seq data processing: split-pipe v0.9.6p, R v4.2.2, Seurat v4.1.0.

snATAC-seq data processing: cellranger-atac-2.0.0, Signac v1.7.0, GenomeInfoDb v1.30.1. Western blot: Image Studio Lite ver5.2 (LI-COR)

Graphing and statistical analysis: GraphPad Prism v8

GitHub repository: https://github.com/YannVRB/Visium-SOR-mouse.git

Image analysis: ImageJ

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

#### Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Sequencing files for bulk RNA-seq, spatial transcriptomic, SPLIT-seq and snATAC-seq have been made publicly available through GSE223066. mm10 reference genome for spatial transcriptomic: https://cf.10xgenomics.com/supp/spatial-exp/refdata-gex-mm10-2020-A.tar.gz mm10 reference genome for BCBio bulk RNA-seq pipeline: https://github.com/bcbio/bcbio-nextgen/blob/master/config/genomes/mm10-resources.yaml mm10 reference genome for snATAC-seq: https://cf.10xgenomics.com/supp/cell-atac/refdata-cellranger-arc-mm10-2020-A-2.0.0.tar.gz mm10 reference genome for split-pipe pipeline: https://ftp.ensembl.org/pub/release-109/fasta/mus\_musculus/dna/ Mus\_musculus.GRCm39.dna.primary\_assembly.fa.gz. https://ftp.ensembl.org/pub/release-109/gtf/mus\_musculus/Mus\_musculus.GRCm39.109.gtf.gz

## Research involving human participants, their data, or biological material

Policy information ab and sexual orientatio		vith human participants or human data. See also policy information about sex, gender (identity/presentation),
Reporting on sex ar	na genaer	N/A
Reporting on race, other socially releve groupings	, ,	N/A
Population characteristics		N/A
Recruitment		N/A
Ethics oversight		N/A
Note that full information	on on the appr	oval of the study protocol must also be provided in the manuscript.
Field-spec		. 9
Please select the one	below that is	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
X Life sciences	В	ehavioural & social sciences
For a reference copy of the	document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>
Life sciend	ces stu	udy design
All studies must discl	ose on these	points even when the disclosure is negative.
þ	orevious studie	each experiment is indicated in the figures and figure legends for each experiment. Sample sizes were estimated based on s in the field (Schurch, N. J. et al. RNA 22, 839-851 (2016), Liu, Y. et al. Bioinformatics 30, 301-304 (2014)). No statistical used to predetermine sample size.
Data exclusions	No animal or sa	mple was excluded from the analysis.
€	expression data	r assessment experiments were replicated at least two times with reproducible results. In addition to our spatial gene i from n=4/group, we also integrated our previous spatial transcriptomics dataset from n=3/group (Bahl, E. et al. bioRxiv E201610) to increase statistical power and improve robustness of the results.
С	cage-mates of t	nental batch, animals were chosen randomly based on their age. No software for randomization were used. Trained mice were the mice in the homecage condition. Similar strategy was also used for AAV-Nr4ADN experiment. Animals were assigned to mbers randomly to minimize any bias.
. 0		for objects for memory were scored by experimenter blind to the treatment groups. RNA and proteins were extracted by lind to the treatment groups. Sections for spatial gene expression were prepared blindly.

# Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & experimental systems	Methods	
n/a Involved in the study	n/a Involved in the study	
Antibodies	ChIP-seq	
Eukaryotic cell lines	Flow cytometry	
Palaeontology and archaeology	MRI-based neuroimaging	
Animals and other organisms		
Clinical data		
Dual use research of concern		
Plants		
1		

### **Antibodies**

Antibodies used

pan-HA (1:1000, Cell signaling), YFP (1:1000, Abcam), Actin (1:10,000, ThermoFisher Scientific), anti-rabbit IRDye 800LT (1:5,000, Ll-COR), anti-mouse IRDye 680CW (1:5000, Ll-COR).

All the antibodies were previously validated by the manufacturer and have presented in their respective websites.

pan-HA (https://www.cellsignal.com/products/primary-antibodies/ha-tag-c29f4-rabbit-mab/3724?\_requestid=3119885).

YFP (https://www.abcam.com/products/primary-antibodies/gfp-antibody-ab290.html).

Actin (https://www.thermofisher.com/antibody/product/beta-Actin-Antibody-clone-AC-15-Monoclonal/AM4302).

## Animals and other research organisms

Policy information about <u>studies involving animals</u>; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in Research</u>

Laboratory animals	Male C57BL/6J mice were purchased from Jackson Laboratories. Mice were maintained under pathogen-free conditions with a 12h light/dark cycle, at a temperature of 21-22 C and a relative humidity of 60-70 % in the Animal care facility of University of Iowa. Male C57BL/6J mice of age 2-3 months were used.
Wild animals	The study did not include any wild animals.
Reporting on sex	Only male mice were included.
Field-collected samples	The study did not include any samples collected at the field.
Ethics oversight	All experiments detailed herein complied with the regulations formulated by the Institutional Animal Care and Use Committee (IACUC) of the University of Iowa.

Note that full information on the approval of the study protocol must also be provided in the manuscript.  $\frac{1}{2} \int_{\mathbb{R}^{n}} \left( \frac{1}{2} \int_{\mathbb{R}^{$